TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
TRACON Pharmaceuticals (NASDAQ: TCON) announced that CEO Charles Theuer will present a corporate overview at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 4:00 PM ET. The company focuses on developing targeted cancer therapeutics through a capital-efficient platform and partnerships with ex-U.S. firms. Key products in its pipeline include Envafolimab for sarcoma and YH001, a CTLA-4 antibody. Interested parties can access the presentation via the TRACON website.
- None.
- None.
SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 4:00pm Eastern Time.
To access a live webcast or replay of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Brian Ritchie |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | (212) 915-2578 |
| mwiggins@traconpharma.com | britchie@lifesciadvisors.com |
FAQ
What major event is TRACON Pharmaceuticals participating in on March 16, 2022?
Who will represent TRACON Pharmaceuticals at the Oppenheimer Conference?
What is TRACON Pharmaceuticals' focus in cancer treatment?
How can I access the TRACON Pharmaceuticals presentation?
What key product is TRACON developing for sarcoma?
What is the ticker symbol for TRACON Pharmaceuticals?
